Feeding impairments associated with plasma sterols in Smith-Lemli-Opitz syndrome

Mark J Merkens1, Nancy L Sinden2, Christine D Brown2

  • 1Institute on Development and Disability, Oregon Health & Science University, Portland, OR; Department of Pediatrics, Doernbecher Children's Hospital, Oregon Health & Science University, Portland, OR.

Insights

Feeding difficulties are common in children with Smith-Lemli-Opitz syndrome (SLOS), often linked to oral sensitivities and biochemical markers. Severity of feeding impairment correlates with 7-dehydrocholesterol levels, offering insights into disease mechanisms.

Area of Science:

  • Biochemistry
  • Pediatrics
  • Genetics

Background:

  • Smith-Lemli-Opitz syndrome (SLOS) is a genetic disorder with complex feeding impairments.
  • Quantitative evaluation of feeding issues in SLOS is crucial for understanding disease severity.

Purpose of the Study:

  • To quantitatively assess feeding impairment in children with SLOS.
  • To correlate feeding difficulties with clinical and biochemical markers of SLOS severity.

Main Methods:

  • Studied 26 children (0.4-19 years) with SLOS.
  • Utilized a scoring system for clinical severity and a novel tool for feeding evaluation.
  • Measured plasma sterol concentrations and analyzed correlations with feeding scores.

Main Results:

  • ~65% of children exhibited oral sensitivities, adverse behaviors, or dysphagia risk.
  • 13 children experienced failure to thrive; 10 required gastrostomy.
  • 7-dehydrocholesterol levels strongly correlated with feeding scores (P < .001); higher levels predicted gastrostomy.

Conclusions:

  • Feeding impairment is prevalent and multifaceted in SLOS.
  • Quantitative assessment of oral sensitivities, behaviors, and dysphagia is feasible.
  • Biochemical SLOS severity, indicated by sterol levels, is linked to feeding function, expanding the SLOS phenotype.
Abstract

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.2K
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Protein Import into the Peroxisomes01:27

Protein Import into the Peroxisomes

Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
4.4K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271